Abstract Cardiovascular disease (CVD) is the leading cause of mortality in women. Differences in pathophysiology, diagnosis, and treatment of women with cardiovascular disease compared with men have become a major focus during the past decades. Guideline of CVD prevention in women drew heavily on the results of randomized clinical trials (RCT). However, data from RCT in women was limited, leading to concerns of women been underrepresented in clinical trials from which guidelines were generated. During the past several years, researchers, physicians, and regulators have made substantial efforts to improve understanding of the sex difference in CVD and to recognize the importance of heart disease in women. The purpose of this review is to evaluate contemporary sex differences in CVD disease management, current representation of women in RCT, and examine factors that may improve women's representation and quality of care in CVD prevention in women.
among women [1] . In patients with acute myocardial infarction (AMI), in-hospital mortality rate is almost 30 % higher in women than in men [1] . Approximately 48 % of inpatient hospital stays for CVD are for women, who account for 43 % of the national cost ($187 billion) associated with these conditions [2] . Most hospitalized patients >65 years of age are women. By 2030, there will be around 72 million people over 65 years old (19 % of the population), and women will progressively outnumber men [3] . These demographics suggest an anticipated increase of burden of CVD in women.
Sex Disparity in CVD
There are well-established differences in disease between men and women [4•, 5-8] . CVD is one of the diseases having the most striking sex-based disparities in disease prevalence. Other diseases that disproportionately affect women compared with men are type 2 diabetes, stroke, infectious disease, and different types of cancer [9] . In the last two decades, several efforts have been made to highlight the significant sex disparities in diagnosis, management, and outcomes across a spectrum of CVD. Blomkalns et al. have shown how women presenting with non-ST segment elevation myocardial infarction (NSTEMI) although being at greater baseline risk are treated less aggressively than men, with a significant lower use of acute and discharge guideline recommended treatments and less cardiac catheterization and subsequent revascularization [6] . A similar treatment disparity was also found in STEMI women and the underutilization of recommended treatment in part explained the higher rate of early death among women [8] . Multiple reasons contribute to the lower use of guideline recommended treatment in women. First, women diagnosed with CVD are on average 10 years older than men, the mean age of first MI is 65 years for men and 72 years for women [1] . Genetic variants and estrogen protection earlier in life may contribute to the late onset of CVD disease in women [10] . Second, women more commonly present with atypical symptoms, such as nausea, vomiting, fatigue and dyspnea, and this results in delayed first medical contact, diagnose and treatment initiation. Third, at the time of first MI women usually present with a higher number of comorbidities than men that make treatment options more challenging [4•, 11] . Finally, lack of evidence-based data on cardiovascular disease management in women due to their limited representation in RCT leaves uncertainties on best treatment strategy.
Persistent Women Underrepresentation in RCT
Several studies in the past decades have revealed low representation of women in cardiovascular clinical trials relative to their disease prevalence [11] [12] [13] . Such disparity has not narrowed in recent years despite the increased awareness of the problem and the understanding of the importance and the need to improve healthcare among women. An updated study of trials published in 2009 revealed that the enrollment of women was unchanged since 2004 [14•] . Women representation in cardiovascular clinical trials still only accounts for 30 % of the trial population. Such proportion is lower in secondary CVD prevention trials and industry funded trials [9, 11] . Women representation is especially lower in cardiovascular disease such as coronary heart disease, heart failure, and hyperlipidemia trials [11] .
Implications of Underrepresentation in RCT
Underrepresentation in RCTs and the subsequent paucity of data to support evidence-based preventative therapies in women have major implications on public health [15, 16] . The first study identifying women being underrepresented in clinical trial was in 1992 [17] . The paucity of women in CVD trials was emphasized as a barrier to making clinical recommendations in the American Heart Association (AHA) evidencebased guidelines for women's prevention of CVD in 2007 [18] . Inadequate representation of women in RCTs does not only translate into the lack of evidence base data for treatment recommendation. Sex differences are also observed in response to drugs, medical devices, and rehabilitation programs [9, [19] [20] [21] . Women have greater risk of developing adverse drug reaction [22] . Several drugs have been withdrawn by FDA due to sex-based adverse event [9] . Medical devices are as well subject to sex bias, based on the significant physiological differences between men and women [19] . Women with ischemic heart disease have less focal lesions, less obstructive disease, and greater micro-vascular damage than men which means in female patients, the disease is harder to diagnose and more difficult to treat with medical devices [23] . On average, 67 % of cardiovascular device trials participants are men [24] . The reasons for lack of female participation in stent clinical trials are not clear yet. However, the lack of available safety and effectiveness data in the female population apparently has resulted in reluctance by cardiologist in using certain devices in women [19] .
Addressing Underrepresentation of Women in RCT
Since then, several actions have been taken from different societies, groups and the government. In 1993 the National Institute of Health (NIH) Revitalization Act legally required 1) inclusion of women and minorities in clinical research, 2) their inclusion to be adequate for valid analysis, and 3) the analyses of outcomes to be performed by sex [25] . Yet, this law applied only to NIH-funded research. In 2005, the Food and Drug Administration (FDA) set recommendations of data collection on race and ethnicity in a standardized pattern for industry studies [26] . There was a request to report clinical findings by sex, race and age but, still, no laws or official policies mandate women inclusion in industry-sponsored clinical trials. To further explore the problem and to discuss how to improve the quality of care for women with heart disease, Duke University Medical Center convened a Duke Clinical Research Institute Think Tank meeting on heart disease in women in 2007 [27] . The final recommendations from the think tank included four key action points: 1) Improve trial design via strengthen statistical method; 2) Improve enrollment in trials by use of proven recruitment and retention strategies; 3) Mandate reporting of primary and secondary results in clinical trials by sex; 4) Create incentives to enhance the performance of research in women.
In 2010, the Coalition of Eliminate Disparities and to Research Inclusion in Clinical Trials (CEDRICT) worked toward identifying barriers to recruitment of women. Lack of disease education among women resulted as being one of the major barriers, followed by insurance status, availability of transportation, and family concerns about risks [28] . The following year in December 2011, the FDA released a draft guidance for industry entitled "Evaluation of sex differences in medical device clinical studies". This document recommended increasing enrollment of women and performing sex-specific analyses [19] .
The same year, in response to a call for better strategies in recruiting women and minorities the Society of Women's Health Research (SWHR) and FDA Office of Women's Health (OWH) hosted "Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities" to encourage experience exchange and collaboration across disciplines [9] . The discussion stressed the underrepresentation of women and minorities in clinical research, and highlighted novel means for improving women and minority enrollment, community-based clinical trial design, and legislative perspectives on guidelines to improve diversity in clinical research.
Perspectives on Women Clinical Research Innovation
1. Better education of patients, health care providers, and the public about CVD in women; 2. Community driven approach that helps health care providers identify women participants; 3. Collaborative strategies for patients' identification and site support, and guideline implementation.
Education and Training
The CEDRICT identified lack of disease education as the major barrier to recruitment [28] . Data from the women Veterans Cohort showed that only 8 to 20 % of them were aware that CVD is the major cause of death for women [29] .
Patients must be educated on the diseases that are most likely to affect them, they need to be aware of possible participation in clinical trials, and also need to know that society and individuals can directly benefit from clinical trial participation. The lack of knowledge of disease prevalence and associated risk factors may result in negligence in their life style, reduced response to symptoms of ischemia in a timely manner, and decreased compliance to treatment. Also poor information leads to skepticism of clinical research, less interest, and willingness to participate in clinical trials. The AHA's 'Go red for women' campaign is a program targeted at educating women on cardiovascular risk or heart disease to help motivate them to change lifestyles, to undergo risk evaluation and treatment-seeking strategies. Thanks to the 'Go red for women' campaign, women are becoming more mindful of their risk for heart disease and have a better understanding of this disease. Recent data show that 54 % of women are aware that there is a high prevalence of CVD among women and that CVD represents the leading cause of death among them, a percentage significantly higher than a couple of decades ago [30] .
On the physician's side, a 2004 national study of physician awareness and adherence to CVD prevention guidelines showed that less than 20 % of physicians knew that more women die each year of CVD than men [31] . Physicians' awareness and training are equally important as patients' education. Physicians must be well-informed of sex-based differences in disease prevalence and presentation, they should be educated on clinical trials and should help patients to understand that their involvement in clinical trials will translate into an improvement in the quality of the health care [9] . The project Increase Minority Participation and Awareness of Clinical Trials (IMPACT) trains physicians to be investigators. Specifically, the project educates minority physicians about clinical research, encourages them either to assume the role of clinical investigator or, at minimum, to develop adequate knowledge of the study to advise their patients about involvement in clinical trials [32] . Finally, sex-sensitive issues, such as childbearing potential and aging, are also important to address when engaging female patients in clinical trials. Women physicians seem to better understand and address these concerns when they enroll women [12] .
A Community Driven Approach to Trial Recruitment
Transparent communication within communities is needed to build up trust. Trial success is in part based on the pretrial preparation that includes identifying the appropriate target patient population. Sponsors of clinical studies and investigators have recently started reaching out to patients at a community level through social events and through the creation of trusted community leaders that can help disseminate useful and valuable information. This new path of early education that seems to be at a more appropriate level for the patients appears to have positive effects on patients' engagement in clinical research. Patients want to feel that they are listened to and appreciated and this applies to a greater extent to women. An example of successful enrollment and retention of women in an HIV clinical trial is the Gender, Race And Clinical Experience (GRACE) study that employed a "community sold the community" strategy where women patients were approached with medial campaign, feminine logo-a butterfly, was used to increase recognition of female patients while retaining anonymity for the study of HIV. Both early engagement of experienced, passionate clinicians, and community advocates were key to success in this study. Social workers were also involved to help female patients feel comfortable and help them understand the importance of the trial [33, 34•] . The trial reached the predefined enrollment goal of two-thirds women and it was a success [34•].
Collaborative Strategies for Patients Identification and Site Support
Strategies need to be made to focus on appropriate site selection; study sites can be targeted to areas with high proportion of CVD female patients. Also, particular attention needs to be paid to those sites that are embracing the difficulties of women enrollment. Continuous site-specific enrollment plans may be implemented for inexperienced investigators. The Gender, Race and Clinical Experience (GRACE) study's experience, has demonstrated that with special monitoring, study sites with initial lower experience outperformed the more experienced study groups [34•] .
Another reason why a collaborative strategy is needed is the suboptimal adherence to guidelines recommendations for CVD prevention in women. Currently there is not an established systematic evaluation of provider's performance in CVD preventive care therefore it is difficult to evaluate to what extent sex/gender difference in delivery of care exists and mainly what are the major barriers [35] . The AHA has published three women-specific evidence-based guidelines between 2004 and 2014 for the prevention of CVD, and a most recent one for stroke prevention in 2014 [36] [37] [38] [39] . Guideline's adherence is limited by whether they are in an easy-read format, the evidence is supported by RCT and they are easy to implement [40] [41] [42] . It will take the joint effort of physicians, patients, community, and regulators to determine whether those improved sex-specific guidelines ultimately are associated with improved clinical outcomes [35] .
Conclusions

CVD remains the leading killer of women in the United
States, the number of women living and dying of CVD exceeds those of men. Women have higher medical care utilization than men [5] . However, women's inclusion in RCT remains low relative to their representation in the affected population. The lack of women-specific safety and effectiveness of data is a barrier to optimal CVD care for women. To improve quality of care of women with CVD, a collaborative effort is needed from physicians, industries, and government and strong commitment to engage communities is required.
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